26 / 38
TARGETED AGENTS
CABOZANTINIB
Chan J, et al. J Clin Oncol 2017; 35, no. 4_suppl 228-228.
Patients with unresectable or metastatic (N=302)
- Well differentiated (G1/G2)
- Progressive disease within 12 months of entry
- No prior cabozantinib; other antiVEGF treatment allowed
Primary endpoint: RECIST response rate
PHASE II
N=20
PANCREAS: After progression to previous targeted agent
N=41
CARCINOID*: Stable dose of SSA for 2 m (prior SSA
required)
Cabozantinib
60 mg/24h
*CARCINOID: Small intestine (N=29), Lung (N=5), Unknown (N=3), Other (rectum, thymus, kidney) (N=4)